



## Zydelig® (idelalisib) – Indication withdrawals

- On January 14, 2022, [Gilead Sciences announced](#) the voluntary withdrawal of the [Zydelig \(idelalisib\)](#) indications for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies and treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.
  - These indications received accelerated approval in 2014 and continued approval was contingent upon confirmatory studies providing evidence supporting clinical benefit in FL and SLL.
- As the treatment landscape for FL and SLL has evolved, enrollment into the confirmatory study has been an ongoing challenge. As a result, Gilead formally notified the FDA of its decision to voluntarily withdraw these indications in the U.S. market.
- This decision does not affect the other approved indication for Zydelig, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
- Gilead will work with the FDA to complete the withdrawal of the FL and SLL indications and with healthcare professionals to support those currently being treated with Zydelig.
- People receiving Zydelig for relapsed FL or SLL should discuss their treatment options with their healthcare provider.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.